Results 151 to 160 of about 1,759,912 (296)

The Final Diagnosis: Evaluating Errors in Cause-of-Death Reporting. [PDF]

open access: yesCureus
Srinivasan K   +9 more
europepmc   +1 more source

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

open access: yesMolecular Oncology, EarlyView.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard   +12 more
wiley   +1 more source

Causas básicas e associadas de morte por Aids, Estado de São Paulo, Brasil, 1998

open access: yesRevista de Saúde Pública
OBJETIVOS: Descrever o padrão da mortalidade devida a Aids segundo causas básica e associadas de morte no Estado de São Paulo, em 1998. MÉTODOS: Os dados sobre a mortalidade e a população residente no Estado de São Paulo, SP, para 1998, foram obtidos na ...
Augusto Hasiak Santo   +2 more
doaj  

Role of Histopathology in Determining the Cause of Death in Medicolegal Autopsies. [PDF]

open access: yesCureus
Mukherjee B   +7 more
europepmc   +1 more source

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

open access: yesMolecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang   +8 more
wiley   +1 more source

Determining the cause of death through mortality surveillance using verbal autopsy in Karachi, Pakistan. [PDF]

open access: yesJ Glob Health
Allana R   +12 more
europepmc   +1 more source

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

open access: yesMolecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy